Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Vicore Pharma Holding AB ( (SE:VICO) ) just unveiled an update.
Vicore Pharma’s 2026 Annual General Meeting approved the 2025 financial statements, decided to retain earnings without a dividend, discharged the board and CEO from liability, and re-elected most board members while adding Peter Guenter as a new director. Directors’ fees were increased, Ernst & Young was reappointed as auditor, and board members gained the option to receive half of their base board fees in restricted share units.
Shareholders also granted the board broad authorization to issue up to 20% new shares, warrants or convertibles to finance acquisitions or company projects, strengthening Vicore’s capital-raising flexibility. An equity-based Board RSU 2026 program of up to 1,185,000 restricted share units and matching warrants was adopted to align board remuneration with shareholder interests and facilitate share-based compensation without immediate cash outlay.
The most recent analyst rating on (SE:VICO) stock is a Buy with a SEK38.00 price target. To see the full list of analyst forecasts on Vicore Pharma Holding AB stock, see the SE:VICO Stock Forecast page.
More about Vicore Pharma Holding AB
Vicore Pharma Holding AB is a Swedish biopharmaceutical company focused on developing innovative treatments, likely in specialty or rare disease areas, and is listed on Nasdaq Stockholm. The company operates through a board-driven governance structure and relies on shareholder authorization to maintain financial flexibility for advancing its clinical and strategic projects.
Average Trading Volume: 520,577
Technical Sentiment Signal: Sell
Current Market Cap: SEK2.81B
For an in-depth examination of VICO stock, go to TipRanks’ Overview page.